AAM’s Francer On Tackling Tactics That Hurt Market Access For Gx, Biosimilars

 
• By Anju Ghangurde
  
Francer_Jeff
Jeff Francer, Interim CEO and General Counsel, Association for Accessible Medicines

More from Business

More from Scrip